论文部分内容阅读
目的探讨替考拉宁在高龄下呼吸道感染患者中的血药浓度与临床疗效、不良反应之间的关系。方法高龄下呼吸道感染病例52例,用替考拉宁治疗5~24 d,观察患者疗效、给药前后肝肾功能指标及不良反应情况;监测患者替考拉宁的谷浓度。结果替考拉宁的谷浓度为(17.1±10.1)mg.L-1,治疗有效组和无效组在血药浓度等方面差异无统计学意义;给药前后肝、肾功能指标差异无统计学意义。结论替考拉宁在治疗下呼吸道感染患者时,血药浓度与疗效之间未见显著相关性,临床应用时应在血药浓度的监测下行个体化治疗。
Objective To explore the relationship between the plasma concentration of teicoplanin in elderly patients with lower respiratory tract infection and clinical efficacy and adverse reactions. Methods 52 elderly patients with lower respiratory tract infection were treated with teicoplanin for 5-24 days. The curative effect, liver and kidney function indexes and adverse reactions before and after treatment were observed. The trough concentrations of teicoplanin were monitored. Results The teicoplanin trough concentration was (17.1 ± 10.1) mg.L-1, there was no significant difference in the plasma concentrations between the effective group and the ineffective group. There was no significant difference in liver and kidney function before and after administration significance. Conclusion Teicoplanin in the treatment of patients with lower respiratory tract infection, there is no significant correlation between plasma concentration and efficacy, clinical application of blood concentration should be monitored in the individual treatment.